Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Activation of a tunicate (Ciona intestinalis) xenobiotic receptor orthologue by both natural toxins and synthetic toxicants.

Fidler AE, Holland PT, Reschly EJ, Ekins S, Krasowski MD.

Toxicon. 2012 Feb;59(2):365-72. doi: 10.1016/j.toxicon.2011.12.008. Epub 2011 Dec 20.

PMID:
22206814
2.

The evolution of farnesoid X, vitamin D, and pregnane X receptors: insights from the green-spotted pufferfish (Tetraodon nigriviridis) and other non-mammalian species.

Krasowski MD, Ai N, Hagey LR, Kollitz EM, Kullman SW, Reschly EJ, Ekins S.

BMC Biochem. 2011 Feb 3;12:5. doi: 10.1186/1471-2091-12-5.

3.

Evaluation of computational docking to identify pregnane X receptor agonists in the ToxCast database.

Kortagere S, Krasowski MD, Reschly EJ, Venkatesh M, Mani S, Ekins S.

Environ Health Perspect. 2010 Oct;118(10):1412-7. doi: 10.1289/ehp.1001930. Epub 2010 Jun 17.

4.

Challenges predicting ligand-receptor interactions of promiscuous proteins: the nuclear receptor PXR.

Ekins S, Kortagere S, Iyer M, Reschly EJ, Lill MA, Redinbo MR, Krasowski MD.

PLoS Comput Biol. 2009 Dec;5(12):e1000594. doi: 10.1371/journal.pcbi.1000594. Epub 2009 Dec 11.

5.

Intrinsic disorder in nuclear hormone receptors.

Krasowski MD, Reschly EJ, Ekins S.

J Proteome Res. 2008 Oct;7(10):4359-72. doi: 10.1021/pr8003024. Epub 2008 Jul 24.

6.

Machine learning methods and docking for predicting human pregnane X receptor activation.

Khandelwal A, Krasowski MD, Reschly EJ, Sinz MW, Swaan PW, Ekins S.

Chem Res Toxicol. 2008 Jul;21(7):1457-67. doi: 10.1021/tx800102e. Epub 2008 Jun 12.

7.

Ligand specificity and evolution of liver X receptors.

Reschly EJ, Ai N, Welsh WJ, Ekins S, Hagey LR, Krasowski MD.

J Steroid Biochem Mol Biol. 2008 May;110(1-2):83-94. doi: 10.1016/j.jsbmb.2008.02.007. Epub 2008 Mar 10.

8.

Evolution of pharmacologic specificity in the pregnane X receptor.

Ekins S, Reschly EJ, Hagey LR, Krasowski MD.

BMC Evol Biol. 2008 Apr 2;8:103. doi: 10.1186/1471-2148-8-103.

9.

Evolution of the bile salt nuclear receptor FXR in vertebrates.

Reschly EJ, Ai N, Ekins S, Welsh WJ, Hagey LR, Hofmann AF, Krasowski MD.

J Lipid Res. 2008 Jul;49(7):1577-87. doi: 10.1194/jlr.M800138-JLR200. Epub 2008 Mar 24.

10.

Functional evolution of the vitamin D and pregnane X receptors.

Reschly EJ, Bainy AC, Mattos JJ, Hagey LR, Bahary N, Mada SR, Ou J, Venkataramanan R, Krasowski MD.

BMC Evol Biol. 2007 Nov 12;7:222.

11.

Notch1 co-opts lymphoid enhancer factor 1 for survival of murine T-cell lymphomas.

Spaulding C, Reschly EJ, Zagort DE, Yashiro-Ohtani Y, Beverly LJ, Capobianco A, Pear WS, Kee BL.

Blood. 2007 Oct 1;110(7):2650-8. Epub 2007 Jun 21.

PMID:
17585052
12.

Human pregnane X receptor antagonists and agonists define molecular requirements for different binding sites.

Ekins S, Chang C, Mani S, Krasowski MD, Reschly EJ, Iyer M, Kholodovych V, Ai N, Welsh WJ, Sinz M, Swaan PW, Patel R, Bachmann K.

Mol Pharmacol. 2007 Sep;72(3):592-603. Epub 2007 Jun 18.

PMID:
17576789
13.

Functional evolution of the pregnane X receptor.

Iyer M, Reschly EJ, Krasowski MD.

Expert Opin Drug Metab Toxicol. 2006 Jun;2(3):381-97. Review.

15.

Notch1 promotes survival of E2A-deficient T cell lymphomas through pre-T cell receptor-dependent and -independent mechanisms.

Reschly EJ, Spaulding C, Vilimas T, Graham WV, Brumbaugh RL, Aifantis I, Pear WS, Kee BL.

Blood. 2006 May 15;107(10):4115-21. Epub 2006 Jan 31.

16.

Apolipoprotein A-I alpha -helices 7 and 8 modulate high density lipoprotein subclass distribution.

Reschly EJ, Sorci-Thomas MG, Davidson WS, Meredith SC, Reardon CA, Getz GS.

J Biol Chem. 2002 Mar 22;277(12):9645-54. Epub 2001 Dec 14.

17.

Supplemental Content

Loading ...
Support Center